Eisner Mark 4
4 · FIBROGEN INC · Filed Mar 10, 2023
Insider Transaction Report
Form 4
FIBROGEN INCFGEN
Eisner Mark
Incoming Chief Medical Officer
Transactions
- Sale
Common Stock
2023-03-10$20.20/sh−6,255$126,334→ 175,176 total - Sale
Common Stock
2023-03-08$21.16/sh−7,363$155,771→ 165,133 total - Award
Common Stock
2023-03-08+7,732→ 172,865 total - Award
Common Stock
2023-03-08+12,451→ 185,316 total - Sale
Common Stock
2023-03-10$20.20/sh−3,885$78,467→ 181,431 total
Footnotes (5)
- [F1]Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
- [F2]Represents the number of shares released for PSU Milestone Grant vested on March 8, 2023.
- [F3]Represents the number of shares released for PSU TSR Grant vested on March 8, 2023.
- [F4]Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU Milestone previously reported in Table I.
- [F5]Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU TSR previously reported in Table I.